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Associations between body mass index (BMI) and the cardiovascular (CV) and kidney 
efficacy of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 
diabetes (T2D) are uncertain; therefore, data analyzed separately from the Liraglutide Effect 
and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial and 
the Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in 
Subjects with Type 2 Diabetes (SUSTAIN 6) were examined. These international, 
randomized, placebo-controlled trials investigated liraglutide and semaglutide (both 
subcutaneous) in patients with T2D and at high risk of CV events. In post hoc analyses, 
patients were categorized by baseline BMI (<25 kg/m2, ≥25–<30 kg/m2, ≥30–<35 kg/m2,  ≥35 
kg/m2), and CV and kidney outcomes with GLP-1RA versus placebo analyzed. All baseline 
BMI data from LEADER (n=9331) and SUSTAIN 6 (n=3290) were included (91% and 92% of 
patients with overweight or obesity, respectively). In SUSTAIN 6, nominally significant 
heterogeneity of semaglutide efficacy by baseline BMI was observed for CV 
death/myocardial infarction/stroke (major adverse CV events: MACE, primary outcome of 
both; pinteraction=0.02); otherwise, there was no statistical heterogeneity for either GLP-1RA 
versus placebo across BMI categories for key CV and kidney outcomes. The lack of 
statistical heterogeneity from these cardiorenal outcomes implies that liraglutide and 
semaglutide may be beneficial for many patients and is likely not to depend on their baseline 
BMI, but further study is needed. 
 
Clinical Trial Registration: ClinicalTrials.gov, NCT01179048 and NCT01720446. 
 




While some glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have been shown to 
reduce major adverse cardiovascular (CV) events (MACE) in people with type 2 diabetes 
(T2D), they are also a recommended treatment when there is a compelling need for such 
patients to lose weight.1,2 Several factors have been linked to these reported CV benefits, 
but their precise roles are unknown.3 Such a factor is baseline BMI, whose impact has only 
been investigated on limited treatment outcomes with GLP-1 RAs.4 Although weight loss 
associated with GLP-1 RA use increases with increasing body mass index (BMI),4 it is 
unknown if other effects vary by BMI. We investigated if the CV and kidney outcomes with 
GLP-1 RAs are consistent across the spectrum of BMI, using data from the Liraglutide Effect 
and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER5) trial and 
the Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in 
Subjects with Type 2 Diabetes (SUSTAIN 66) analyzed separately.  
 
Materials and methods 
Study design  
The LEADER and SUSTAIN 6 trial designs have been published.5,6 In brief, both trials were 
double-blind and placebo-controlled. Patients with T2D and at high risk of CV events were 
randomly assigned to the GLP-1 RA or placebo (once-daily subcutaneous [s.c.] liraglutide 
1.8 mg or maximum tolerated dose vs placebo in LEADER, 1:1 ratio; once weekly s.c. 
semaglutide 0.5 mg or 1.0 mg vs volume-matched placebo in SUSTAIN 6, 1:1:1:1 ratio 
[pooled as semaglutide vs placebo for analyses]), with all patients otherwise treated 
according to standard of care.5,6 Key inclusion criteria in both trials were age ≥50 years with 
established CV disease (previous coronary, cerebrovascular or peripheral vascular disease), 
heart failure (New York Heart Association class II or III), or chronic kidney disease stage ≥3; 
or age ≥60 years with at least one CV risk factor (microalbuminuria or proteinuria, 
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hypertension with left ventricular hypertrophy, left ventricular systolic or diastolic dysfunction, 
or an ankle–brachial index of <0.9).5,6 Major exclusion criteria included use of GLP-1 RAs, 
dipeptidyl peptidase-4 inhibitors, pramlintide or rapid-acting insulin, and recent history of an 
acute coronary or cerebrovascular event.5,6  
 
The primary composite outcome in both trials was first occurrence of MACE (CV death, 
nonfatal myocardial infarction or nonfatal stroke). The key secondary expanded outcome 
(expanded MACE) also included hospitalization for unstable angina or heart failure, or 
revascularization. The secondary composite renal outcome (termed nephropathy) was 
comprised of new-onset or persistent macroalbuminuria, persistent doubling of serum 
creatinine level and creatinine clearance <45 mL/min/1.73 m2, the need for continuous renal-
replacement therapy or death from kidney disease. Both trials were approved by institutional 
review boards or ethics committees for each centre; all patients provided written informed 
consent.5,6 
 
Weight and height were measured by investigators at baseline and BMI was calculated. BMI 
was also assessed at designated visits throughout both trials.5,6 
 
Statistical methods  
Details of primary statistical analyses conducted in these trials have been described.5,6 For 
the present post hoc analyses, the effects of liraglutide and semaglutide on the time-to-first 
primary MACE, expanded MACE, CV death and nephropathy were evaluated by baseline 
BMI category, separately for the two trials. BMI was categorized based on cut-off values 
described by the World Health Organization as <25 kg/m2, ≥25 to <30 kg/m2, ≥30 to <35 
kg/m2 and ≥35 kg/m2, defining overweight as BMI ≥25 kg/m2 and obesity as BMI ≥30 kg/m2.7 
The significance of the differences between the baseline characteristics across these BMI 
categories was assessed using a Kruskal-Wallis test for continuous variables and a chi-
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square test for categorical variables regardless of treatment group. The Cochran-Armitage 
trend test was used to analyze event rates across BMI groups in the placebo groups of both 
trials. The hazard ratios (HRs) and 95% confidence interval (CI) for treatment versus 
placebo were calculated using Cox proportional hazard regression models with treatment 
and BMI category as fixed factors and included a treatment-by-BMI term to test for 
quantitative interaction between both. The models were adjusted for baseline characteristics 
related to cardiorenal risk (sex, smoking status, anti-hyperglycaemic treatments, prior CV 
events, geographic region, age, diabetes duration, estimated glomerular filtration rate), with 
p-interaction <0.05 considered significant. No adjustments for multiple testing were 
performed.  
 
Quadratic spline regression was applied using Cox proportional hazard regression to 
analyze treatment differences in time-to-first MACE by continuous baseline BMI. The 
percentage weight loss by BMI category was calculated over 3 years for LEADER and 104 
weeks for SUSTAIN 6, including p-interaction for both. All analyses were performed using 
the software package SAS (version 9.4).  
 
Results 
The disposition and baseline characteristics of trial participants have been published.5,6 In 
LEADER, a total of 9340 patients were randomized (4668 to liraglutide; 4672 to placebo), 
with a median follow-up of 3.8 years.5 In SUSTAIN 6, 3297 patients were randomized (1648 
to semaglutide; 1649 to placebo), with a median follow-up of 2.1 years.6  
The proportion of patients in LEADER with a baseline BMI of <25 kg/m2, ≥25 to <30 kg/m2, 
≥30 to <35 kg/m2 and ≥35 kg/m2 were 9%, 29%, 32%, and 30%, respectively, and in 
SUSTAIN 6 were 8%, 28%, 33% and 31%, respectively (Table S1). Baseline characteristics 
varied across the BMI categories within each trial (Table S1). Notably, in LEADER, the 
mean diabetes duration was longest in the BMI <25 kg/m2 category versus the other BMI 
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categories, with a similar trend in SUSTAIN 6. As expected, a greater percentage of patients 
were treated with insulin at baseline with increasing baseline BMI in both trials (Table S1). 
The percentage of patients with established CV disease was similar across the BMI 
categories in LEADER (p=0.30; range: 80.3–82.2%; Table S1), while in SUSTAIN 6 it 
differed (p=0.02; range: 78.7–84.7%; Table S1). Within both trials, the mean estimated 
glomerular filtration rates were similar across the BMI categories (p=0.27 for LEADER; 
p=0.14 for SUSTAIN 6; Table S1). 
The placebo event rates for MACE, expanded MACE and CV death were similar across BMI 
categories within each trial (Table S2). In SUSTAIN 6, risk for nephropathy declined with 
increasing BMI category (ptrend=0.0002), and although the nephropathy event rate declined in 
LEADER, it did not reach significance (ptrend=0.18) (Table S2).  
When analyzing data from the treatment groups, only the interaction for MACE in SUSTAIN 
6 demonstrated significance; for all others, there was no statistically significant heterogeneity 
of the treatment effects of liraglutide or semaglutide versus placebo across baseline BMI 
groups (Figure 1). Correspondingly, p-interaction values for treatment-by-BMI for MACE, 
expanded MACE and CV death in LEADER were 0.34, 0.22, and 0.79, respectively; and in 
SUSTAIN 6 were 0.02, 0.27, and 0.82, respectively.  
For new-onset or worsening nephropathy, there was no heterogeneity of treatment efficacy 
across the BMI categories, with p-interaction values of 0.92 for LEADER and 0.21 for 
SUSTAIN 6 (Figure 2). 
In the regression analysis of baseline BMI as a continuous parameter, liraglutide showed 
consistent benefits across BMI categories in analysis of time-to-first MACE, within the 
quartile boundaries, where 50% of the events occurred. Semaglutide also showed similar 
results across baseline BMI values for MACE (Figure S1). 
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There was no significant interaction between treatment and BMI category for percentage 
weight loss with either liraglutide (p-interaction=0.07; Figure S2A) or semaglutide (p-
interaction=0.51; Figure S2B).  
Discussion 
The present results of post hoc analyses from LEADER and SUSTAIN 6 show that there 
was no heterogeneity in the CV and renal benefits of liraglutide and semaglutide versus 
placebo across the spectrum of baseline BMI evaluated either categorically or continuously, 
excepting a nominally significant interaction observed by baseline BMI category for the effect 
of semaglutide on MACE. These data should be considered by prescribers when choosing 
these agents for CV risk reduction in appropriate patients. 
The exact nature of the relationship between any baseline characteristic, including BMI, and 
CV benefit of liraglutide and semaglutide (via glycaemic control and/or weight loss and/or 
other mechanisms) remains difficult to establish,3,8 with published meta-analysis results 
demonstrating that baseline BMI was not associated with achieved glycaemic control across 
seven different anti-hyperglycaemic treatments.9 Thus, the dose-response curves for any 
treatment may differ for MACE, glucose levels and weight, and our analyses have 
demonstrated that there appeared to be generally no effect of baseline BMI on MACE. 
Also, prior data evaluating the associations of weight loss on CV outcomes are varied. The 
Look AHEAD trial randomized patients with overweight/obesity and T2D to intensive lifestyle 
(diet and exercise) intervention versus control.10 Despite significantly greater weight loss 
achieved in the intervention group, there was no significant difference in CV disease-related 
morbidity and mortality.10  Conversely, in the Albiglutide and cardiovascular outcomes in 
patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes) trial that 
randomized patients with T2D at high CV risk to the GLP-1 RA albiglutide or placebo, a 
statistically significant 22% reduction in first occurrence of CV death, myocardial infarction or 
stroke (HR, 0.78 [95% CI 0.68;0.90]) was observed with albiglutide versus placebo. While 
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weight loss was marginally greater in the albiglutide group versus placebo at 8 and 16 
months, the differences were less than 1 kg (–0.66 and –0.83 kg, respectively), and at 28 
months, weight in both the placebo and albiglutide groups was similar to their baseline 
values.11 Yet another type of association was evident in the Researching Cardiovascular 
Events with a Weekly Incretin in Diabetes (REWIND) trial, where treatment of patients with 
T2D with dulaglutide resulted in a significant decrease in CV events (HR, 0.88 [95% CI 
0.79;0.99) and a significant decrease in body weight (-1.46 kg [95% CI 1.25; 1.67]) versus 
placebo.12 Mediation analyses utilizing data from such trials may provide evidence as to how 
weight loss impacts CV risk, but to date, it appears that the size of any such mediation of 
body weight on CV outcomes may be small with liraglutide.13 
The many mechanisms that have been proposed to underlie the cardioprotective effects of 
GLP-1 RAs are complex. They include anti-inflammatory effects, attenuation of cardiac 
ischaemic injury through a variety of direct and indirect actions on the myocardium and 
coronary arteries, modification of lipid synthesis and secretion, and improvement in 
endothelial dysfunction, among others.3 For example, in one study, liraglutide and 
semaglutide reduced plaque lesion development through altering inflammatory pathways in 
mouse models of atherosclerosis.14 These pathways could be involved in the significant 
improvements in the carotid intima-media thickness of patients who were treated with 
liraglutide for 8 months versus baseline.15 Such cardioprotective mechanisms of GLP-1 RAs 
appear to be independent of the lipid levels of patients.15  
The renal protective effects of GLP-1 RAs have been less well studied than the 
cardioprotective effects and may be linked to renal tubular effects, oxidative stress and 
haemodynamic effects.16 For liraglutide and semaglutide, renal benefits were found in 
LEADER and SUSTAIN 6, where they were investigated as secondary, composite 
endpoints.5,6 Analysis of the nephropathy components revealed that the renal benefits were 
driven by new or persistent macroalbuminuria.6,17 Within our post hoc analyses, the renal 
benefit with semaglutide appeared to decrease with increasing BMI, but this effect 
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modification by BMI status was not statistically significant. However, in the placebo-treated 
population of SUSTAIN 6, it was evident that nephropathy decreased with increasing BMI, 
which may seem counterintuitive, but fits with some studies of patients with chronic kidney 
disease and end stage renal disease.18 The reason for the discrepancy between the 
LEADER and SUSTAIN 6 data in this particular regard remains unknown, but could be 
related to any of the baseline characteristics that varied by BMI category in SUSTAIN 6, but 
not in LEADER (e.g. established CV disease). 
There were limitations to this study. These were post hoc analyses with numerous potential 
confounding factors (including not being powered to assess efficacy for CV and renal 
outcomes across baseline BMI strata and being of relatively short follow-up), and the 
analyses were not adjusted for differences in insulin, sodium-glucose cotransporter-2 
inhibitor and CV medication use. Baseline BMI categories were not corrected for application 
to Asian patients, who comprised 9.6% of the study population, and the BMI categories were 
not protected by the trial randomization, resulting in heterogeneous subgroups. Only 
baseline BMI was analyzed, and results were more consistent with the larger, post-approval 
LEADER trial, compared with the smaller, pre-approval SUSTAIN 6 trial. With just one of the 
many interaction tests yielding a nominally significant p-value, the validity of this finding is 
uncertain and may be a spurious finding as these analyses were post hoc and did not 
include correction for multiplicity of testing. These analyses used data pertaining to 
liraglutide and semaglutide only; further analyses with datasets utilizing other GLP-1 RA data 
will help clinicians to understand if a class effect underpins these results. Although pooling 
data from the two trials may have increased the power of this analysis, due to the larger size 
of LEADER versus SUSTAIN 6, we chose to analyze the data separately, to provide a clear 
indication of what happened with each treatment. 
Conclusion 
These results from post hoc analyses of the LEADER and SUSTAIN 6 trials suggest  that 
there are consistent CV and renal benefits of liraglutide and semaglutide across baseline 
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BMI categories in patients with T2D and high CV risk, but they need to be confirmed in future 
studies.   
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Figure 1. Cardiovascular outcomes by baseline body mass index category in 
a) LEADER and b) SUSTAIN 6 
 
Primary and expanded MACE analyses adjusted for sex, smoking status, 
antihyperglycaemic treatments, prior CV events, geographic region, age, diabetes duration, 
estimated glomerular filtration rate. Smoking status was not adjusted for in the SUSTAIN 6 
analysis for CV death, due to low event numbers. 
†Primary MACE: composite of CV death, nonfatal MI and nonfatal stroke ‡Expanded MACE: 
components of primary MACE plus revascularization (coronary only in LEADER; coronary or 
peripheral in SUSTAIN 6) or hospitalization for unstable angina pectoris or heart failure. 
BMI, body mass index (in kg/m2); CI, confidence interval; CV, cardiovascular; HR, hazard 




Figure 2: Renal outcomes by baseline body mass index category in a) LEADER and 
b) SUSTAIN 6 
 
LEADER analysis adjusted for sex, smoking status, antihyperglycaemic treatments, prior 
cardiovascular events, geographic region, age, diabetes duration, estimated glomerular 
filtration rate. SUSTAIN 6 analysis adjusted for sex, antihyperglycaemic treatments, prior 
cardiovascular events, geographic region, age, diabetes duration, estimated glomerular 
filtration rate (smoking status was omitted due to low event numbers). 
†Nephropathy: new or persistent macroalbuminuria, doubling of serum creatinine, creatinine 
clearance <45 mL/min/1.73 m2, end-stage kidney disease or death from kidney disease. 
BMI, body mass index (in kg/m2); CI, confidence interval; HR, hazard ratio. 
